-
Bio-Rad Labs (BIO) Misses Q4 EPS by 20c; offers outlook
-
Bio-Rad Labs (BIO) Tops Q3 EPS by 31c, provides outlook
-
Bio-Rad co-founder Alice Schwartz dies at 99
-
UBS highlights Bio-Rad Labs' (BIO) margin expansion opportunity, reiterates Buy rating
-
RBC Capital: 'We Are Buyers of Bio-Rad Labs (BIO)'; PT Raised to $409
-
Bio-Rad Labs (BIO) Tops Q2 EPS by 88c; updates outlook
-
Bio-Rad names Rajat Mehta executive vice president of global operations
-
Bio-Rad launches four new digital PCR platforms following acquisition
-
Cantor Fitzgerald: BIO CEO says US Needs a Biomanufacturing Renaissance
-
Bio-Rad Labs (BIO) Tops Q1 EPS by 74c; updates outlook
-
Qiagen (QGEN) said targeted by activist Fivespan Partners
-
Bio-Rad Labs (BIO) PT Lowered to $285 at Jefferies
-
OncoCyte (OCX) Reports Successful 2024; Sets Stage for 2025 Catalysts
-
Bio-Rad Labs (BIO) PT Lowered to $400 at Citi
-
Bio-Rad Labs (BIO) Tops Q4 EPS by 4c; offers outlook
-
Bio-Rad Labs (BIO) to Acquire Stilla Technologies
-
OncoCyte (OCX) prices $29.1 million equity offering at $2.05 per share
-
Bio-Rad Labs (BIO) Tops Q3 EPS by 85c, Beats on Revenue
-
Citi Upgrades Bio-Rad Labs (BIO) to Buy
-
Palantir, Dell to join S&P 500
-
Bio-Rad Labs (BIO) Appoints Jon DiVincenzo as COO
-
Bio-Rad Labs (BIO) Tops Q2 EPS by $1.10, Misses on Revenue; Offers Q3 Guidance
-
Citi Reiterates Neutral Rating on Bio-Rad Labs (BIO)
-
This stock offers one of the most favorable long-term risk/rewards in biotech: RBC

